AU2013249820C1 - HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof - Google Patents

HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof Download PDF

Info

Publication number
AU2013249820C1
AU2013249820C1 AU2013249820A AU2013249820A AU2013249820C1 AU 2013249820 C1 AU2013249820 C1 AU 2013249820C1 AU 2013249820 A AU2013249820 A AU 2013249820A AU 2013249820 A AU2013249820 A AU 2013249820A AU 2013249820 C1 AU2013249820 C1 AU 2013249820C1
Authority
AU
Australia
Prior art keywords
leu
ala
ser
glu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013249820A
Other languages
English (en)
Other versions
AU2013249820A1 (en
AU2013249820B2 (en
Inventor
Roli K. Hirata
David W. Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013249820(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of AU2013249820A1 publication Critical patent/AU2013249820A1/en
Application granted granted Critical
Publication of AU2013249820B2 publication Critical patent/AU2013249820B2/en
Publication of AU2013249820C1 publication Critical patent/AU2013249820C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
AU2013249820A 2012-04-17 2013-03-15 HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof Active AU2013249820C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625314P 2012-04-17 2012-04-17
US61/625,314 2012-04-17
PCT/US2013/032058 WO2013158292A1 (en) 2012-04-17 2013-03-15 Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof

Publications (3)

Publication Number Publication Date
AU2013249820A1 AU2013249820A1 (en) 2014-10-23
AU2013249820B2 AU2013249820B2 (en) 2017-07-20
AU2013249820C1 true AU2013249820C1 (en) 2018-10-25

Family

ID=48045753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013249820A Active AU2013249820C1 (en) 2012-04-17 2013-03-15 HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof

Country Status (12)

Country Link
US (2) US20150056225A1 (enExample)
EP (2) EP2838548B1 (enExample)
JP (4) JP2015514421A (enExample)
AU (1) AU2013249820C1 (enExample)
CA (2) CA3085032A1 (enExample)
DK (1) DK2838548T5 (enExample)
ES (1) ES2959382T3 (enExample)
FI (1) FI2838548T3 (enExample)
HU (1) HUE063231T2 (enExample)
PL (1) PL2838548T3 (enExample)
PT (1) PT2838548T (enExample)
WO (1) WO2013158292A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373460B (es) * 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
KR20170075013A (ko) * 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
EP3215623A4 (en) * 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016112779A1 (en) * 2015-01-17 2016-07-21 Zhejiang University Modified cells evoking reduced immunogenic responses
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
HK1257518A1 (zh) 2016-01-11 2019-10-25 Novartis Ag 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
CA3022227A1 (en) * 2016-04-27 2017-11-02 University Health Network (Uhn) Peptide-hla complexes and methods of producing same
KR20190103373A (ko) * 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN110637083A (zh) * 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
JP7372920B2 (ja) 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112955542A (zh) * 2018-07-13 2021-06-11 L·杰罗姆罗 非免疫原性工程化组织及其生产方法和用途
US20210322473A1 (en) * 2018-07-18 2021-10-21 The General Hospital Corporation Modified t cells and methods of their use
CN110819592A (zh) * 2018-08-13 2020-02-21 赛元生物科技(杭州)有限公司 一种通用供体干细胞及其制备方法
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CA3138597A1 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
CA3170361A1 (en) * 2020-02-07 2021-08-12 Juntendo Educational Foundation Cytotoxic t cells derived from human t cell-derived ips cells
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
WO2022038411A1 (en) 2020-08-19 2022-02-24 Astellas Pharma, Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
EP4200023A4 (en) 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
CN114350612A (zh) * 2020-09-28 2022-04-15 未来智人再生医学研究院(广州)有限公司 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物
CN114276995A (zh) * 2020-09-28 2022-04-05 未来智人再生医学研究院(广州)有限公司 一种表达ctla-4阻遏分子的多能干细胞及其衍生物
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
CN114517184A (zh) * 2020-10-30 2022-05-20 未来智人再生医学研究院(广州)有限公司 一种表达adipsin的多能干细胞或其衍生物及应用
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
CN114525254A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达fgf-21的多能干细胞或其衍生物及应用
CN114457033A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达il-6阻断物的多能干细胞衍生物及其应用
CN114525257A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用
CN114457030A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IgE阻断物的多能干细胞或其衍生物及应用
CN114457024A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN114645021A (zh) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
CN114657131A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达尿酸氧化酶的多能干细胞或其衍生物
CN114657130A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
CN114657138A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114717192A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用
CN114717193A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
TW202309268A (zh) 2021-05-07 2023-03-01 安斯泰來再生醫藥協會 產生成熟肝細胞的方法
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US20260002124A1 (en) 2022-07-01 2026-01-01 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
TW202417614A (zh) 2022-08-23 2024-05-01 安斯泰來再生醫藥協會 用於治療眼部病症的感光救援細胞（prc）組成物及方法
CN118207165B (zh) * 2022-12-07 2026-03-20 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
EP4735585A1 (en) 2023-06-30 2026-05-06 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
EP0995798A1 (en) * 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
CA3157027A1 (en) * 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
JP2014513948A (ja) * 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIRATA, R.K. et al. "A Knockout of beta-2-microglobulin in a human embryonic stem cell by AAV-mediated gene targeting" "7th Australasian gene therapy society meeting", THE JOURNAL OF GENE MEDICINE, 2011, vol. 13, no. 7-8, page 436, P9 *
MADSEN, L. ET AL, "Mice lacking all conventional MHC class II genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, 1999, vol. 96, pages 10338 - 10343 *
PEIJNENBURG, A. ET AL, IMMUNOGENETICS, 2000, vol. 51, no. 1, pages 42 - 49 *
VAN EGGERMOND, M.C.J.A ET AL, "Transcriptional silencing of RFXAP in MHC class II-deficiency", MOLECULAR IMMUNOLOGY, 2008, vol. 45, no. 10, pages 2920 - 2928 *

Also Published As

Publication number Publication date
PT2838548T (pt) 2023-10-13
JP2022162047A (ja) 2022-10-21
CA2870571C (en) 2025-09-16
DK2838548T3 (en) 2023-08-21
CA3085032A1 (en) 2013-10-24
AU2013249820A1 (en) 2014-10-23
ES2959382T3 (es) 2024-02-26
JP2024144548A (ja) 2024-10-11
WO2013158292A1 (en) 2013-10-24
AU2013249820B2 (en) 2017-07-20
US20150056225A1 (en) 2015-02-26
JP2019068856A (ja) 2019-05-09
JP2015514421A (ja) 2015-05-21
PL2838548T3 (pl) 2024-02-05
HUE063231T2 (hu) 2024-01-28
JP7531925B2 (ja) 2024-08-13
EP4253409A3 (en) 2023-12-06
EP2838548B1 (en) 2023-07-19
EP4253409A2 (en) 2023-10-04
EP2838548A1 (en) 2015-02-25
FI2838548T3 (fi) 2023-10-02
US20190365876A1 (en) 2019-12-05
DK2838548T5 (en) 2024-08-05
JP7130571B2 (ja) 2022-09-05
CA2870571A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
JP7601916B2 (ja) 蝸牛および前庭細胞に核酸を送達するための物質および方法
AU2021204620A1 (en) Central nervous system targeting polynucleotides
EP2838548B1 (en) Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
KR20210080375A (ko) 암 면역요법을 위한 재조합 폭스바이러스
AU2016343979A1 (en) Delivery of central nervous system targeting polynucleotides
KR102628872B1 (ko) 세포의 증식을 제어하기 위해 세포 분열 좌위를 사용하기 위한 도구 및 방법
CN109451729B (zh) 工程化病毒载体减少了炎症和免疫反应的诱导
KR20180097631A (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
KR20170026358A (ko) 리소좀 저장 장애의 치료를 위한 아데노연관 바이러스 벡터
CN108136048A (zh) 左旋多巴的系统合成和调节
CN111733174B (zh) 一种分离的核酸分子及其用途
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
CN112218882A (zh) Foxp3在经编辑的cd34+细胞中的表达
CN113260704B (zh) CYP4V2和RdCVF在制备药物中的用途
CN111511918A (zh) 抑制病毒载体诱导的炎症反应的组合物和方法
KR20240000541A (ko) 키메라 항원 수용체(car)-t 세포
KR20210137427A (ko) Car t 세포 방법 및 작제물
KR20220023962A (ko) 파브리병을 치료하기 위한 조성물, 디바이스 및 방법
CN114606251A (zh) 以外泌体为载体的dna递送系统
CN115916985A (zh) 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
CN111909918B (zh) 一种内溶素突变体及其编码基因与应用
KR20240032718A (ko) 키메라 항원 수용체(car)-t 세포
CN115247181A (zh) 一种用于制备脱发模型猪的核移植供体细胞的试剂盒及其制备方法
HK40082332A (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
RU2781083C2 (ru) Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HLA CLASS II DEFICIENT CELLS, HLA CLASS I DEFICIENT CELLS CAPABLE OF EXPRESSING HLA CLASS II PROTEINS, AND USES THEREOF

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ RUSSELL, DAVID W. AND KIRATA, ROLI K.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE SUPPLEMENT TO THE OFFICIAL JOURNAL DATED 23 NOV 2017

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ RUSSELL, DAVID W. AND HIRATA, ROLI K

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ RUSSELL, DAVID W. AND HIRATA, ROLI K.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 JUN 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 JUN 2018